Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patientsReport as inadecuate




Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients - Download this document for free, or read online. Document in PDF available to download.

BMC Cardiovascular Disorders

, 14:196

Coronary artery disease

Abstract

BackgroundPlasma calprotectin is a potential biomarker of cardiovascular disease CVD, insulin resistance IR, and obesity. We examined the relationship between plasma calprotectin concentrations, CVD manifestations and the metabolic syndrome MetS in patients with type 2 diabetes mellitus T2DM in order to evaluate plasma calprotectin as a risk assessor of CVD in diabetic patients without known CVD.

MethodsAn automated immunoassay for determination of plasma calprotectin was developed based on a fecal Calprotectin ELIA, and a reference range was established from 120 healthy adults. Plasma calprotectin concentrations were measured in 305 T2DM patients without known CVD. They were screened for carotid arterial disease, peripheral arterial disease PAD, and myocardial ischemia MI by means of carotid artery ultrasonography, peripheral ankle and toe systolic blood pressure measurements, and myocardial perfusion scintigraphy.

ResultsThe reference population had a median plasma calprotectin concentration of 2437 ng-mL 2.5-97.5% reference range: 1040–4262 ng-mL. The T2DM patients had significantly higher concentrations 3754 ng-mL, p < 0.0001, and within this group plasma calprotectin was significantly higher in patients with MetS p < 0.0001 and also in patients with autonomic neuropathy, PAD, and MI compared with patients without p < 0.001, p = 0.021 and p = 0.043, respectively. Plasma calprotectin was by linear regression analysis found independently associated with BMI, C-reactive protein, and HDL cholesterol. However, plasma calprotectin did not predict autonomic neuropathy, PAD, MI or CVD when these variables entered the multivariable regression analysis as separate outcome variables.

ConclusionT2DM patients had higher concentrations of plasma calprotectin, which were associated with obesity, MetS status, autonomic neuropathy, PAD, and MI. However, plasma calprotectin was not an independent predictor of CVD, MI, autonomic neuropathy or PAD.

Trial registration numberNCT00298844

KeywordsCalprotectin MRP8-14 Cardiovascular disease Inflammation Type 2 diabetes Obesity Metabolic syndrome Automated assay Reference range AbbreviationsCVDCardiovascular disease

IRInsulin resistance

MetSMetabolic syndrome

T2DMType 2 diabetes mellitus

CADCoronary artery disease

PADPeripheral arterial disease

MIMyocardial ischemia

BMIBody mass index

HDLHigh-density lipoprotein

MRP8-14Myeloid-related protein 8-14

RAGEReceptor for advanced glycation end products

DAMPDamage-associated molecular pattern

MAPKMitogen-activated protein kinase

BPBlood pressure

WHOWorld Health Organization

MPSMyocardial perfusion scintigraphy

SSSSummed stress score

HOMA-IRHomeostasis model assessment of insulin resistance

IQRInterquartile range

CIMTCarotid intima media thickness

TLRToll-like receptor.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2261-14-196 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Lise Pedersen - Mads Nybo - Mikael Kjær Poulsen - Jan Erik Henriksen - Jordi Dahl - Lars Melholt Rasmussen

Source: https://link.springer.com/







Related documents